カテゴリー： Allied Market Research, 世界, 医療/バイオ

がんモノクローナル抗体の世界市場2021-2031：機会分析・産業予測

◆英語タイトル：Cancer Monoclonal Antibodies Market By Antibody Type (Murine, Chimeric, Humanized), By Application (Blood Cancer, Breast Cancer, Lung Cancer, Others), By End User (Hospitals and Clinics, Research and Academic Institute/Laboratories): Global Opportunity Analysis and Industry Forecast, 2021-2031

Allied Market Researchが発行した調査報告書（ALD23MY012）◆商品コード：ALD23MY012
◆発行会社（リサーチ会社）：Allied Market Research
◆発行日：2023年2月
◆ページ数：300
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：バイオ
◆販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

アライドマーケットリサーチ社の市場調査書では、世界のがんモノクローナル抗体市場規模が2021年には55,640.00百万ドルから2031年には106,825.10百万ドルに達し、予測期間中にCAGR 7.0％増加すると見込まれています。こちらの調査書は、がんモノクローナル抗体の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場概要、抗体種類別（マウス抗体、キメラ抗体、ヒト化抗体）分析、用途別（血液癌、乳がん、肺がん、その他）分析、エンドユーザー別（病院＆診療所、研究＆学術機関/実験所）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などを掲載しています。なお、本書には、Roche Holdings Ltd、Johnson & Johnson、Pfizer Inc.、Novartis AG、AstraZeneca plc、Merck & Co. Inc.、Celgene Limited、Bistrol-Myers Squibb、Eli Lilly & Co.、Abbvie Incなどの企業情報が含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のがんモノクローナル抗体市場規模：抗体種類別
- マウス抗体の市場規模
- キメラ抗体の市場規模
- ヒト化抗体の市場規模
・世界のがんモノクローナル抗体市場規模：用途別
- 血液癌における市場規模
- 乳がんにおける市場規模
- 肺がんにおける市場規模
- その他用途における市場規模
・世界のがんモノクローナル抗体市場規模：エンドユーザー別
- 病院＆診療所における市場規模
- 研究＆学術機関/実験所における市場規模
・世界のがんモノクローナル抗体市場規模：地域別
- 北米のがんモノクローナル抗体市場規模
- ヨーロッパのがんモノクローナル抗体市場規模
- アジア太平洋のがんモノクローナル抗体市場規模
- 中南米/中東・アフリカのがんモノクローナル抗体市場規模
・競争状況
・企業情報

世界のがんモノクローナル抗体市場規模は、2021年に556億4,000万ドル、2031年には1,068億2,510万ドルに達すると予測され、年平均成長率は7.0%となる見込みです。
モノクローナル抗体は、人体内の特定の部位に対する合成抗体です。癌を引き起こす細胞の表面で、抗原として機能します。モノクローナル抗体には数多くの種類があり、それぞれが1種類の抗原にのみ結合するように作られています。これらの抗体は、ある種のがんを含む多くの病気の治療に頻繁に使用されています。この抗体は、放射性物質や注射薬を癌細胞に直接投与します。ある調査によると、放射性がん治療は世界中で最も頻繁に使用されているがん治療の一種です。
高齢者人口の増加、がん罹患率の上昇、新しいワクチンや治療法に対する需要の増加は、がんモノクローナル抗体市場の成長を促進すると予想される主な要因の一部です。肺がんなど、さまざまな種類のがんの有病率が世界中で上昇しているため、効果的な治療法に対する需要が高まっており、研究者や科学者は研究努力を加速させ、がんに対する効果的なモノクローナル医薬品を生み出すよう促しています。 これらの要因が、予測期間中の市場成長を促進すると予測されています。
市場は、最先端技術を用いたモノクローナル抗体の作製に伴う高コストが大きな制約となっています。複雑な製造手順、高価な生物学的・化学的成分、臨床試験、必要な有効性・安全性・品質試験などが、がんモノクローナル抗体検査のコスト高を招いています。多くのジスルフィド結合や翻訳後修飾を含むモノクローナル抗体の大量合成には、高価な特殊機器の使用が必要です。これらすべてが、予測期間中の市場成長を妨げる主な要因です。
世界各国の政府は、先進的ながん診断・治療法の開発に投資しており、これががんモノクローナル抗体市場の成長を後押しすると予想されます。さらに、多くの国が国民のがん治療へのアクセスを提供することを目的としたプログラムやイニシアチブを確立しており、がんモノクローナル抗体検査の需要をさらに促進しています。政府支援の増加も、より正確で信頼性が高く、費用対効果の高い新しいがんモノクローナル抗体検査の開発を後押ししています。これにより、早期診断されるがん患者数が増加し、がんモノクローナル抗体検査の需要が高まっています。これががんモノクローナル抗体市場の上昇に寄与しています。
COVID-19のパンデミックは、がんモノクローナル抗体検査業界に悪影響を及ぼしました。パンデミックの初期段階において、コロナウイルス2019（COVID-19）は、材料の供給、生産、物流業務に大きな困難をもたらし、研究および医薬品開発活動に大きな影響を与えました。COVID-19のパンデミックが始まると、世界中のほとんどの企業や研究イニシアチブは操業を停止し、試薬やその他の実験器具の市場需要が減少しました。

本レポートで紹介する主要企業は、F. Hoffmann-La Roche Ltd.、Bristol Myers、Squibb Co.、Merck & Co.、GlaxoSmithKline plc、Johnson & Johnson、Amgen, Inc.、Novartis AG、AstraZeneca plc、Eli Lilly and Company、AbbVieなどです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までのがんモノクローナル抗体市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、がんモノクローナル抗体の市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・がんモノクローナル抗体市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国について、世界市場に対する収益貢献度をマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界のがんモノクローナル抗体市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
エンドユーザー別
病院＆診療所
研究＆学術機関／研究所

抗体タイプ別
マウス
キメラ
ヒト化抗体

用途別
血液がん
乳がん
肺がん
その他

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
イギリス
フランス
スペイン
イタリア
その他のヨーロッパ
・アジア太平洋
中国
日本
インド
韓国
オーストラリア
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
アラブ首長国連邦
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Roche Holdings Ltd
Johnson & Johnson
Pfizer Inc.
Novartis AG
AstraZeneca plc
Merck & Co. Inc.
Celgene Limited
Bistrol-Myers Squibb
Eli Lilly & Co.
Abbvie Inc

❖ レポートの目次 ❖

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Key Regulation Analysis
3.7. Market Share Analysis
3.8. Patent Landscape
3.9. Regulatory Guidelines
3.10. Value Chain Analysis
CHAPTER 4: CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Murine
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Chimeric
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Humanized
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Blood Cancer
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Breast Cancer
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Lung Cancer
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals and Clinics
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Research and Academic Institute/Laboratories
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Antibody Type
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Antibody Type
7.2.5.1.3. Market size and forecast, by Application
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Antibody Type
7.2.5.2.3. Market size and forecast, by Application
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Antibody Type
7.2.5.3.3. Market size and forecast, by Application
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Antibody Type
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Antibody Type
7.3.5.1.3. Market size and forecast, by Application
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. UK
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Antibody Type
7.3.5.2.3. Market size and forecast, by Application
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. France
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Antibody Type
7.3.5.3.3. Market size and forecast, by Application
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Spain
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Antibody Type
7.3.5.4.3. Market size and forecast, by Application
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Italy
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Antibody Type
7.3.5.5.3. Market size and forecast, by Application
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Antibody Type
7.3.5.6.3. Market size and forecast, by Application
7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Antibody Type
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Antibody Type
7.4.5.1.3. Market size and forecast, by Application
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. Japan
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Antibody Type
7.4.5.2.3. Market size and forecast, by Application
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Antibody Type
7.4.5.3.3. Market size and forecast, by Application
7.4.5.3.4. Market size and forecast, by End User
7.4.5.4. South Korea
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Antibody Type
7.4.5.4.3. Market size and forecast, by Application
7.4.5.4.4. Market size and forecast, by End User
7.4.5.5. Australia
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Antibody Type
7.4.5.5.3. Market size and forecast, by Application
7.4.5.5.4. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Antibody Type
7.4.5.6.3. Market size and forecast, by Application
7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Antibody Type
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Antibody Type
7.5.5.1.3. Market size and forecast, by Application
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Antibody Type
7.5.5.2.3. Market size and forecast, by Application
7.5.5.2.4. Market size and forecast, by End User
7.5.5.3. UAE
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Antibody Type
7.5.5.3.3. Market size and forecast, by Application
7.5.5.3.4. Market size and forecast, by End User
7.5.5.4. South Africa
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Antibody Type
7.5.5.4.3. Market size and forecast, by Application
7.5.5.4.4. Market size and forecast, by End User
7.5.5.5. Rest of LAMEA
7.5.5.5.1. Key market trends, growth factors and opportunities
7.5.5.5.2. Market size and forecast, by Antibody Type
7.5.5.5.3. Market size and forecast, by Application
7.5.5.5.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Roche Holdings Ltd
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.2. Johnson & Johnson
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.3. Pfizer Inc.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.4. Novartis AG
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.5. AstraZeneca plc
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.6. Merck & Co. Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.7. Celgene Limited
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.8. Bistrol-Myers Squibb
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.9. Eli Lilly & Co.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.10. Abbvie Inc
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot

LIST OF TABLES
TABLE 01. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 02. CANCER MONOCLONAL ANTIBODIES MARKET FOR MURINE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 03. CANCER MONOCLONAL ANTIBODIES MARKET FOR CHIMERIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 04. CANCER MONOCLONAL ANTIBODIES MARKET FOR HUMANIZED, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 05. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 06. CANCER MONOCLONAL ANTIBODIES MARKET FOR BLOOD CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 07. CANCER MONOCLONAL ANTIBODIES MARKET FOR BREAST CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 08. CANCER MONOCLONAL ANTIBODIES MARKET FOR LUNG CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 09. CANCER MONOCLONAL ANTIBODIES MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 11. CANCER MONOCLONAL ANTIBODIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. CANCER MONOCLONAL ANTIBODIES MARKET FOR RESEARCH AND ACADEMIC INSTITUTE/LABORATORIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 15. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 17. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 18. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 20. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 21. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 22. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 23. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 24. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 25. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 26. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 27. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 29. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 30. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 31. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 33. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 34. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 36. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 37. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 39. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 40. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 42. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 43. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 45. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 46. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 47. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 48. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 49. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 53. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 55. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 56. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 58. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 59. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 61. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 62. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 63. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 64. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 65. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 67. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 68. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 70. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 71. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 72. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 73. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 74. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 75. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 76. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 77. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 78. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 79. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 80. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 81. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 82. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 83. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 84. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 86. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 87. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 88. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 89. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 90. ROCHE HOLDINGS LTD: KEY EXECUTIVES
TABLE 91. ROCHE HOLDINGS LTD: COMPANY SNAPSHOT
TABLE 92. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 93. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 94. PFIZER INC.: KEY EXECUTIVES
TABLE 95. PFIZER INC.: COMPANY SNAPSHOT
TABLE 96. NOVARTIS AG: KEY EXECUTIVES
TABLE 97. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 98. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 99. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 100. MERCK & CO. INC.: KEY EXECUTIVES
TABLE 101. MERCK & CO. INC.: COMPANY SNAPSHOT
TABLE 102. CELGENE LIMITED: KEY EXECUTIVES
TABLE 103. CELGENE LIMITED: COMPANY SNAPSHOT
TABLE 104. BISTROL-MYERS SQUIBB: KEY EXECUTIVES
TABLE 105. BISTROL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 106. ELI LILLY & CO.: KEY EXECUTIVES
TABLE 107. ELI LILLY & CO.: COMPANY SNAPSHOT
TABLE 108. ABBVIE INC: KEY EXECUTIVES
TABLE 109. ABBVIE INC: COMPANY SNAPSHOT

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ がんモノクローナル抗体の世界市場2021-2031：機会分析・産業予測(Cancer Monoclonal Antibodies Market By Antibody Type (Murine, Chimeric, Humanized), By Application (Blood Cancer, Breast Cancer, Lung Cancer, Others), By End User (Hospitals and Clinics, Research and Academic Institute/Laboratories): Global Opportunity Analysis and Industry Forecast, 2021-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 電動式人工補綴の世界市場2021-2031：機会分析・産業予測
  • 酸素ボンベ＆濃縮器の世界市場2021-2031：機会分析・産業予測
  • 遺伝子合成の世界市場2021-2031：機会分析・産業予測
  • 体外受精（IVF）顕微鏡の世界市場2021-2031：機会分析・産業予測
  • 高頻度換気装置（HFV）の世界市場2021-2031：機会分析・産業予測

    • ◆H&Iグローバルリサーチのお客様（例）◆